CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell su...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Thayaparan, Thivyan, Petrovic, Roseanna M., Achkova, Daniela Y., Zabinski, Tomasz, Davies, David M., Klampatsa, Astero, Parente-Pereira, Ana C., Whilding, Lynsey M., van der Stegen, Sjoukje JC, Woodman, Natalie, Sheaff, Michael, Cochran, Jennifer R., Spicer, James F., Maher, John
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706532/
https://ncbi.nlm.nih.gov/pubmed/29209570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1363137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados